SCHEMBL2980997

SCHEMBL2980997

CC(C)(C)OC(=O)N1C=C(O)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.43
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.39
GPR119 Q8TDV5 5/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CTSK P43235 1/20 0.37
EPHX1 P07099 1/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3505154 0.85 ESR2 (0.45) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL17481737 0.81 USP2 (0.41) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL18499551 0.80 USP2 (0.49) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL20690515 0.80 ALDH1A1 (0.40) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL17942084 0.79 GPR119 (0.39) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL17942066 0.77 USP2 (0.41) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL29877296 0.77 ESR2 (0.40) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL12465383 0.76 ESR2 (0.37) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL17942035 0.76 HTT (0.37) ESR2USP2SMN1; SMN2NR1H2GPR119
SCHEMBL14878683 0.75 USP2 (0.39) ESR2USP2SMN1; SMN2NR1H2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119320379-A Indazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-01-17 CN disclosed
CN-113874367-B Indazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-09-13 CN disclosed
US-11713313-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-01 US disclosed
US-20210122744-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-29 US disclosed
US-10738043-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-11 US disclosed
EP-3316887-B1 GLS1 INHIBITORS FOR TREATING DISEASE UNIV TEXAS (US) 2020-04-08 EP disclosed
US-20190031651-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-01-31 US disclosed
EP-1950198-B1 PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE TORAY FINECHEMICALS CO LTD (JP) 2014-08-06 EP disclosed
US-7772406-B2 Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2010-08-10 US disclosed
US-20090093643-A1 Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2009-04-09 US disclosed
EP-1950198-A1 PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE Toray Fine Chemicals Co., Ltd. (JP) 2008-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738043-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 ESR2 3385/4885USP2 2989/4885SMN1; SMN2 2191/4885
US-20190031651-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 ESR2 3385/4885USP2 2989/4885SMN1; SMN2 2191/4885
US-20210122744-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 ESR2 3385/4885USP2 2989/4885SMN1; SMN2 2191/4885
US-11713313-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 ESR2 3385/4885USP2 2989/4885SMN1; SMN2 2191/4885
US-20090093643-A1 Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative HPD, PAH, DHPS ESR2 4570/4885USP2 3655/4885SMN1; SMN2 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.